respiratory syncytial virus

News

MSD preparing to take on Beyfortus with RSV antibody

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting

News

Roche launches 'revolutionary' pathogen detection tech

Roche has introduced the first test based on a new technology – called TAGS – that it believes could revolutionise testing for infectious diseases by allowing high-throughput detection to b

News

GSK gets EU okay for RSV shot in younger age group

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could l

News

MSD stakes claim to RSV prevention market for infants

MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-gro

News

Moderna gets FDA okay for RSV vaccine mResvia

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax C

News

FDA delays decision on Moderna’s RSV vaccine

Moderna’s first attempt to expand its commercial activities beyond COVID-19 vaccines, its respiratory syncytial virus (RSV) shot, has suffered a delay in the US.

MSD preparing to take on Beyfortus with RSV antibody

Roche launches 'revolutionary' pathogen detection tech

GSK gets EU okay for RSV shot in younger age group

MSD stakes claim to RSV prevention market for infants

Moderna gets FDA okay for RSV vaccine mResvia

FDA delays decision on Moderna’s RSV vaccine

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

respiratory syncytial virus

Editor's Picks